Calistoga - Top 15 Biotech VC Deals of 2010

Company: Calistoga Pharmaceuticals
Based: Seattle, WA
Amount: $40.22M

Investors: Quogue Capital, Alta Partners, Amgen Ventures, Frazier Healthcare, Three Arch Partners and Latterell Venture Partners

Scoop: Since its $40.22 million Series C round, Calistoga has continued to turn heads, most recently from its $600 million buyout by Gilead Sciences. Their last funding round brought the company's total VC take to $100 million over four years, mostly for its cancer drug CAL-101 and a rheumatoid arthritis treatment. The company received $375 million upfront from Gilead, and stands to make another $225 million through milestone payments.

Calistoga - Top 15 Biotech VC Deals of 2010
Read more on

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.